Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTZ-301 in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT07121946Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LTZ-301 in non-Hodgkin lymphoma (NHL) (3 arms). Primary endpoint: Safety and Tolerability at 54 weeks. Started Jan 2026; status: recruiting.
02
Drugs
LTZ-301
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07121946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121946.